美国食品药品监督管理局(FDA)于周一发布警告,要求奥泽姆皮克(Ozempic)、维格威(Wegovy)等流行GLP-1受体激动剂类药物的制造商修改药品标签,增加关于非动脉炎性前部缺血性视神经病变(NAION)的风险提示 323。该罕见眼部疾病可能导致单眼无痛性视力突然下降甚至永久性失明 23。受此警告影响的药物包括诺和诺德公司的Ozempic和Wegovy、礼来公司的Mounjaro和Zepbound以及赛诺菲公司的Soliqua 3。
据美国眼科医师学会数据显示,NAION的发病率约为每10万人中有2到10人 1。欧洲药品管理局去年的数据表明,服用司美格鲁肽的人群中,高达每1万人可能有1人受到NAION影响 2。此外,一项两年前的研究指出,在17,000名患者中,服用司美格鲁肽者被诊断为NAION的可能性是未服药者的四倍 2。尽管哈佛医学院教授Joseph Rizzo评价这一发现“重要但初步”,并呼吁进行更多研究,但FDA审查认为用药者存在NAION事件增加的风险 2。目前尚不清楚此类药物导致NAION的具体机制,且由于患者群体中常见糖尿病、心血管疾病、高血压、高胆固醇、代谢综合征及阻塞性睡眠呼吸暂停等NAION已知风险因素,确切关联性难以完全确定 1。
针对FDA的要求,相关制药公司如诺和诺德回应称,现有数据尚未证明因果联系,并强调患者不应在未咨询医生的情况下擅自停药 2。
The U.S. Food and Drug Administration (FDA) has issued a new safety warning requiring manufacturers of popular GLP-1 receptor agonist medications to add information about the risk of non-arteritic anterior ischemic optic neuropathy (NAION) to drug labels 123. The announcement, made on Monday, applies to several widely used weight-loss and diabetes treatments, including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, and Sanofi’s Soliqua 123. NAION is a rare eye condition that can cause sudden, painless vision loss in one eye, potentially leading to permanent blindness 123.
Regulators determined that users of these medications face an increased risk of this "rare" adverse event, although the exact biological mechanism remains unclear 12. The prevalence of NAION is estimated at 2 to 10 cases per 100,000 people according to data from the American Academy of Ophthalmology 1. Previous research highlights varying degrees of association: a study two years ago involving 17,000 patients found that those taking semaglutide were four times more likely to be diagnosed with NAION than non-users, while European Medicines Agency data suggested that up to 1 in 10,000 semaglutide users might be affected 2. Experts note that establishing a direct causal link is difficult because many patients using GLP-1 drugs already possess common risk factors for NAION, such as diabetes, hypertension, cardiovascular disease, high cholesterol, metabolic syndrome, and obstructive sleep apnea 12.
In response to the FDA's directive, pharmaceutical companies have urged caution regarding abrupt discontinuation of therapy. Novo Nordisk stated that current data do not prove a causal relationship and emphasized that patients should not stop taking their medication without consulting a healthcare provider 2. Joseph Rizzo, a professor at Harvard Medical School, described the findings as "important but preliminary," indicating that further investigation is necessary to fully understand the scope of the risk 2.
评论
还没有评论,欢迎留下第一条。